Bone density measurement methods during androgen deprivatio
Recruiting
- Conditions
- Prostate cancer, andogen deprivation, bone densityProstaatkanker, androgeen deprivatie, botdichtheid
- Registration Number
- NL-OMON22104
- Lead Sponsor
- SFG, Rotterdam, The Netherlands
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 51
Inclusion Criteria
Age >18 years
1. Indication for ADT as treatment for nonmetastatic prostate cancer according to the
Bolla schedule;
Exclusion Criteria
Pre-existing indication for osteoporosis treatment, i.e. before the baseline DEXA
scan.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Agreement between the change in Achilles T-scores and the change in DEXA scan<br>T-scores.
- Secondary Outcome Measures
Name Time Method Association of repeated delta T-scores over time of the DEXA and Achilles scans<br /><br>• Association between (absolute) Achilles T-scores and (absolute) DEXA T-scores at<br>each available time point.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bone density changes in prostate cancer patients on androgen deprivation therapy?
How does androgen deprivation therapy compare to standard-of-care treatments in managing bone density in prostate cancer patients?
Which biomarkers are most predictive of bone density response to androgen deprivation therapy in prostate cancer?
What are the most common adverse events associated with androgen deprivation therapy in prostate cancer patients with bone density concerns?
Are there any combination therapies or alternative approaches that enhance bone density preservation during androgen deprivation therapy for prostate cancer?